Evidence map›Paper›PMID 40825766›Full record

ArticleCell death & disease2025

Inhibition of ATM enhances the immunogenicity of triple-negative breast cancer by promoting MHC-I expression.

Jiazhen Li, Chenying Liu, Xiaolong Qian, Xiaozi Wang, Hui Sun, Lu Wang, Huiqin Xue, Yuanming Song, Jiamei Liu, Yafang Zhao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jiazhen Li *Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Chenying Liu *Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Xiaolong Qian *Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Xiaozi WangDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Hui SunDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Lu WangDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Huiqin XueDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Yuanming SongDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Jiamei LiuDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Yafang ZhaoDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Yumian JiaDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Fengxia QinDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Tianhua ZhangDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China.
Xiaojing GuoDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, West Huanhu Road, 300060, Tianjin, China. guoxiaojing@tjmuch.com.ORCID http://orcid.org/0000-0003-3753-2900

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81772840
6 · The paper itself

Abstract

The immunotherapy has achieved some efficacy in triple-negative breast cancer (TNBC), but the benefit population is limited, primarily due to an abnormal immune microenvironment. Thus, it is necessary to explore new molecular targets to enhance the immunogenicity of TNBC cells and improve their responsiveness to immunotherapy. We found that a key component of the DNA repair system, Ataxia telangiectasia mutated (ATM), may function as an immune response inhibitor. In this study, the inverse correlation between ATM and CD8

Indexed as

Ataxia Telangiectasia Mutated ProteinsHistocompatibility Antigens Class ITriple Negative Breast NeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansLymphocytes, Tumor-InfiltratingMiceSTAT1 Transcription FactorTumor MicroenvironmentAtaxia Telangiectasia Mutated ProteinsATM protein, humanHistocompatibility Antigens Class ISTAT1 Transcription Factor

Identifiers

PMID40825766
PMCPMC12361503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.